119 related articles for article (PubMed ID: 38630132)
1. Still high risk? A review of translocation t(14;16) in multiple myeloma.
Mian H; Kaiser M; Fonseca R
Am J Hematol; 2024 Jun; ():. PubMed ID: 38874195
[TBL] [Abstract][Full Text] [Related]
2. Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.
Al-Ani F; Bermejo JM; Mateos MV; Louzada M
Thromb Res; 2016 May; 141():84-90. PubMed ID: 26986753
[TBL] [Abstract][Full Text] [Related]
3. Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines.
Charalampous C; Shah D; Kumar S; Chakraborty R
Ann Hematol; 2024 Apr; ():. PubMed ID: 38630132
[TBL] [Abstract][Full Text] [Related]
4. Venous thromboembolism risk with contemporary lenalidomide-based regimens despite thromboprophylaxis in multiple myeloma: A systematic review and meta-analysis.
Chakraborty R; Bin Riaz I; Malik SU; Marneni N; Mejia Garcia A; Anwer F; Khorana AA; Rajkumar SV; Kumar S; Murad MH; Wang Z; Khan SU; Majhail NS
Cancer; 2020 Apr; 126(8):1640-1650. PubMed ID: 31913498
[TBL] [Abstract][Full Text] [Related]
5. Heparin versus aspirin thromboprophylaxis adds independent value to IMPEDE-VTE score for venous thrombosis prediction in multiple myeloma.
Bravo-Perez C; Fernández-Caballero M; Soler-Espejo E; Garcia-Torralba E; Sorigue M; García-Malo MD; Jerez A; Vicente V; Roldán V; de Arriba F
J Thromb Thrombolysis; 2021 Oct; 52(3):848-853. PubMed ID: 33649980
[TBL] [Abstract][Full Text] [Related]
6. Prediction and Prevention of Cancer-Associated Thromboembolism.
Khorana AA; DeSancho MT; Liebman H; Rosovsky R; Connors JM; Zwicker J
Oncologist; 2021 Jan; 26(1):e2-e7. PubMed ID: 33274815
[TBL] [Abstract][Full Text] [Related]
7. Mitigating the risk of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory-based therapy.
Covut F; Sanfilippo KM
Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):363-367. PubMed ID: 36485142
[TBL] [Abstract][Full Text] [Related]
8. Assessing the risk of venous thromboembolism in multiple myeloma.
Sanfilippo KM
Thromb Res; 2020 Jul; 191 Suppl 1():S74-S78. PubMed ID: 32736783
[TBL] [Abstract][Full Text] [Related]
9. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial.
Voorhees PM; Sborov DW; Laubach J; Kaufman JL; Reeves B; Rodriguez C; Chari A; Silbermann R; Costa LJ; Anderson LD; Nathwani N; Shah N; Bumma N; Efebera YA; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Orlowski RZ; Shain KH; Cowan AJ; Dinner S; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG
Lancet Haematol; 2023 Oct; 10(10):e825-e837. PubMed ID: 37708911
[TBL] [Abstract][Full Text] [Related]
10. Risk of Venous Thromboembolism in Multiple Myeloma Patients During the Immediate Peri-Autologous Hematopoietic Cell Transplantation Phase.
Awada H; Hajj Ali A; Anwer F; Shahzad R; Mazzoni S; Williams L; Chaulagain C; Hamilton B; Sauter C; Khouri J
Clin Appl Thromb Hemost; 2023; 29():10760296231177678. PubMed ID: 37277999
[TBL] [Abstract][Full Text] [Related]
11. External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs.
Dima D; Li A; Granat LM; Dhillon P; Chamseddine F; Yalamanchali A; Mirzai S; Wei W; Samaras CJ; Valent J; Anwer F; Khouri J
Br J Haematol; 2023 Apr; 201(2):280-284. PubMed ID: 36604838
[TBL] [Abstract][Full Text] [Related]
12. Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival.
Charalampous C; Goel U; Kapoor P; Binder M; Buadi FK; Dingli D; Dispenzieri A; Fonder AL; Gertz MA; Gonsalves W; Hayman SR; Hobbs MA; Hwa YL; Kourelis T; Lacy MQ; Leung N; Lin Y; Warsame R; Kyle RA; Rajkumar SV; Kumar S
Am J Hematol; 2023 Mar; 98(3):413-420. PubMed ID: 36588396
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis.
Gulati S; Eckman MH
Ann Intern Med; 2023 Jan; 176(1):1-9. PubMed ID: 36571839
[TBL] [Abstract][Full Text] [Related]
14. Daratumumab plus lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma: Analysis of vascular thrombotic events in the GRIFFIN study.
Sborov DW; Baljevic M; Reeves B; Laubach J; Efebera YA; Rodriguez C; Costa LJ; Chari A; Silbermann R; Holstein SA; Anderson LD; Kaufman JL; Shah N; Pei H; Patel S; Cortoos A; Bartlett JB; Vermeulen J; Lin TS; Voorhees PM; Richardson PG
Br J Haematol; 2022 Nov; 199(3):355-365. PubMed ID: 36111391
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
